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ADENO-ASSOCIATED VIRAL VECTORS FOR TISSUE-SPECIFIC GENE 
DELIVERY IN VIVO 
WAJEEHA QURESHI 
 
ABSTRACT 
Objective: Clinical gene therapy is increasingly becoming a favorable method for 
the targeting and treatment of various human diseases. One such gene-transfer 
method is the use of adeno-associated viruses (AAVs) as a tool for tissue-
specific delivery of genes. AAV vectors are attractive vector candidates due to 
their low pathogenicity, biological safety, and ability to infect both dividing and 
quiescent cells for sustained gene expression. We sought to develop a protocol 
for the production, propagation, purification, and characterization of various AAV 
serotypes to determine their tropism and to observe their integrative and 
expressive abilities using different reporter genes in vitro and in vivo. 
Methods: We used subcloning techniques to introduce our genes of interest into 
an AAV expression plasmid and recombined with two other AAV vectors required 
for packaging, cell-specific targeting, and integration capabilities. Serotypes 
AAV1/8/9 and 5 which are cross-packaged with the prototype AAV2 were used to 
individually target cardiac cells/skeletal muscle and neuronal cells respectively in 
eC57BL/6J mice. Viral particles were propagated in vitro and purified using an 
iodixanol gradient. Purified AAV vectors were introduced into cells in culture and 
injected into live mice via tail vein injection or using robotic stereotaxic surgery 
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directly into brain opposite saline controls to determine expression capabilities in 
vitro and in vivo, respectively. Live mice were imaged using the IVIS 
bioluminescent imaging system to measure luciferase luminescent readout. 
Separately, sections were acquired from the brains of the mice injected with 
serotype AAV2/5 and imaged using live cell imaging fluorescence microscopy to 
demonstrate integrative ability of the vectors into neurons based on GFP reporter 
signal.   
Results: A protocol for the generation of neuron-specific AAVs was developed for 
the successful integration of the reporter gene GFP. The reporter gene was 
cloned into the AAV expression cassette. Efficient transfection methods were 
determined along with optimal culture conditions for the propagation of the viral 
particles in vitro. Promoter-driven reporter gene expression was observed in 
serotype-targeted cell types in vitro and in vivo. Expression was limited to 
neuronal cells based on AAV serotype specificity and SYN1 promoter. Integration 
and expression of the luciferase gene was not observed in the IVIS system.  
Conclusion: Here we demonstrate expression of a GFP reporter in specific 
neuronal cell types which indicates successful integration and expression abilities 
of AAV vectors. This specific tissue-targeting technique using the AAV vector 
highlights the potential for the further development of these vectors as a 
promising gene transfer system. 
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INTRODUCTION 
 Clinical gene therapy is rapidly becoming a favorable tool to combat a 
multitude of diseases that afflict a variety of organs and cell types. Virtually all 
cells in the body contain a genetic identification code in the form of 
deoxyribonucleic acid (DNA) – a signature that we can take advantage of to 
therapeutically treat a myriad of conditions. Numerous strategies allow for the 
introduction of new genetic material into cells to replace mutations in patients’ 
genes that can lead to dysfunctional proteins or otherwise defective gene 
products. One such method is the use of viruses that can act as gene-delivery 
tools. The use of adeno-associated viruses (AAV) as vectors is especially 
promising due to their potential for cell-specific gene delivery coupled with 
tendency to induce little to no immunogenic response and biological safety. Our 
research group sought to demonstrate AAV transduction capabilities in different 
cell types using reporter genes in cells in culture and in a live animal model.  
 
Gene Therapy 
Clinical gene therapy harnesses the genetic transfer abilities of different 
technologies to introduce new genetic material into either somatic or germline 
cells in the body to treat or to prevent a disease. Virtually all cells in patients are 
susceptible as targets of genetic exchange; however, there is a different 
consequence of transferring nucleic acid into a somatic, or nonreproductive cell, 
versus a cell of the germline (eggs or sperm). The latter technique involves the 
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enhancement of DNA in a postmitotic cell that then passes the change to all 
subsequent generations. This practice is currently not active and remains largely 
a theoretical concern (Anderson, 1985). Apart from these ethical considerations, 
gene therapy promises great potential for the treatment of numerous inherited 
and acquired diseases such as congenital blindness, hypoxia, and even cancer 
(Bennet, J. et al., 2012) (Rhim, Lee, & Lee, 2013) (Dachs, Dougherty,Stratford, & 
Chaplin, 1997).  
Gene Therapy Limitations 
Although new technologies for safe and effective gene delivery methods 
are being developed and tested rapidly, there are currently limited methods to 
ensure that non-specific expression of the therapeutic genes does not occur. 
Transcriptional control is a necessary component of the application of transgene 
methods to ensure that no off-target tissues or proteins are affected. Inducible 
gene expression is a method of regulating transcription and subsequent 
processes and can occur in a few ways. This is the goal in treating a disease 
such as cancer, where there is necessity for the selected targeting and killing of 
tumor cells. Similarly, in cardiovascular or neurological disorders where there is a 
defect in the function of one protein in a specific cell or tissue type, it would be 
essential to control for the cell-specific insertion of the corrected gene via a 
selective vector. To date, both viral and non-viral delivery agents have been used 
with varying degrees of success. Non-viral methods involving the use of cationic 
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polymeric and lipid based carriers are attractive due to their safety advantages 
but have notably low efficiency and no targeting ability compared to some of the 
viral alternatives available (Brown, Schatzlein, & Uchegbu, 2001). 
Viral Vectors 
Naturally-evolved properties of viruses include their ability to deliver 
nucleic acid to a specific host cell type while evading immunosurveillance by that 
host, which makes them ideal candidates for gene therapy tools. A multitude of 
viral vehicle types, or vectors, exist and have been modified in the laboratory for 
therapeutic applications. Retroviruses, adenoviruses, adeno-associated viruses, 
and herpes simplex viruses all have unique profiles and can be used for a variety 
of applications.  
Viral vectors for gene therapy were first introduced as a revolutionary new 
treatment method with low risk of side effects for otherwise untreatable diseases. 
However, early clinical trials brought to light inefficiencies associated with the use 
of some of these vectors. Early recombinant prototypes did not provide sufficient 
delivery of the genes into target cells or failed to persist, leading to short-lived 
expression. Greater understanding of vector biology and of viral vectors-host 
interactions has led to improved efficiency and some clinical trial successes, 
however (Thomas, 2003).  
 Today, there are numerous gene targets linked to diseases that are 
amenable to the use of viral vectors for gene transfer. No single virus category is 
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likely suitable for all treatment types, but some have great potential to be 
effective therapeutic candidates in the long-term. Ideal properties of a viral vector 
candidate include the ability to propagate and be stably reproduced, incorporate 
into the host cell type and genetic locus of interest, ability to be purified to high 
titer, and finally to deliver genetic material with low risk of side effects. In addition 
to the identification and generation of the vector, a therapeutic gene must be 
cloned and a comprehensive understanding of the pathogenesis of the diseases 
is required to ensure targeting and delivery to the appropriate cell type. 
Retroviruses and adenoviruses are the most oft-used vectors in clinical trials and 
it is anticipated that the use of adeno-associated viruses and herpes simplex 
virus will also gain traction in the clinic (Tani, Faustine, & Sufian, 2011). 
Viral vectors have been extensively engineered in the laboratory through 
research and experiments with animal models to minimize any associated health 
risks and immunogenic responses. Lentiviruses, members of the retrovirus 
family, were derived from the human immunodeficiency virus (HIV), though they 
retain less than 5% of the parent genome and less than 25% is incorporated into 
packaging constructs, thereby almost eliminating the potential for the retro-
generation of competent HIV particles. Adenoviruses have also been extensively 
modified to reduce their induction of inflammatory responses in the host. Helper-
dependent adenoviruses that include the deletion of all viral genes (that could 
cause a cytotoxic response) have been developed and have long term potential 
due also to their prolonged transgene expression. (Thomas 2003). Adeno-
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associated viruses are gaining in popularity because they can affect a variety of 
cell types selectively, and can do so without cytotoxic effects. In virtually all viral 
vector systems, non-essential genes are removed and remaining essential genes 
are spread among different plasmids to ensure safety. Gene components are 
distinguished by those that are necessary to be provided in cis (on the same 
plasmid) or in trans (on a separate plasmid) as the insert-containing plasmid. 
AAVs require ITR (inverted terminal repeat) elements to be provided in cis for 
efficient multiplication of the AAV genome, and the Rep and Cap genes to be 
provided in trans for packaging and assembly of the final virion.  
Adeno-associated Viruses 
Adeno-associated viral (AAV) vectors are increasingly becoming more 
popular as gene delivery tools owing to their safety and efficacy as demonstrated 
by promising clinical trials and regulatory approvals. AAVs are a human virus 
type that can infect both dividing and quiescent cells. They can integrate as a 
provirus to propagate or form a lytic infection. “Adeno-associated” virus derives 
its name from its inability to initiate successful viral infection without the function 
of helper adeno- or herpes-viruses. It was first discovered as a contaminant of 
purified adenovirus preparations and was thought to be either a precursor of the 
mature adenoviral particle or a residual product of the degradation of the adeno- 
virion (Atchison, et al., 1965) (Hoggan, Blacklow, & Rowe, 1966). In the absence 
of a helper virus, AAV cannot produce progeny viral particles, but it can integrate 
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into host site-specific chromosome to form a latent infection. Host cells carrying 
an AAV provirus that subsequently become infected with a helper virus allow for 
the AAV genome to become excised and to proceed to a productive infection 
cycle (Hoggan, Thomas, Thomas, & Johnson, 1972). AAV can also productively 
replicate when cells are treated with chemical or physical agents that exert 
genotoxic activity (Berns &Linden, 1995) 
The AAV particle is relatively small virion of 18- to 25-nm and consists of 
an approximate 5-kilobase single-stranded DNA genome that is packaged into an 
icosahedral capsid composed of 60 proteins (Berns, 1990). The recombinant 
vectors contain two 145-basepair inverted terminal repeats that form a T-shaped 
hairpin at both ends; these are the only cis-acting elements that are retained from 
the wildtype AAV genome (Xiao, Xiao, Li, & Samulski, 1997). Recombinant 
vectors are straightforward to produce – they consist of a transgene cassette, 
where the gene of interest in cloned in between the two viral inverted terminal 
repeats. Once cloned into this plasmid, it is used to co-transfect packaging cells 
with factors that provide the AAV Rep and Cap proteins required for final virion 
assembly. Variations in the amino acid sequences of the capsid proteins provide 
naturally-occurring serotype diversity among AAV vectors; in application this 
property proves valuable since it can provide the ability to target specific cells 
based on serotype-receptor specificity. (Zacchigna, Zentilin, Giacca, 2014). To 
date, 13 distinct AAV serotypes have been identified for application (Mietzsch, et 
al., 2014), all of which are hybridized with the prototype AAV2.  
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AAV2 provides the genetic backbone for the complete virus particle and is 
the most well-characterized. All other serotypes of the recombinant vectors are 
hybridized with this original archetype and allow for targeting of specific cells 
based on co-receptor binding. The virus docks primarily by binding to heparin 
sulfate proteoglycan (HSPG) and then is assisted in internalization by binding to 
coreceptors. Not all of the AAV serotype receptors are known, but many of their 
tropisms have been well studied and described. The tissue-targeting ability of 
AAVs can be further enhanced through genetic regulation by the placement of 
the gene of interest under the control of a tissue-specific promoter.  
AAV Vectors for Gene Therapy 
AAV vectors are demonstrating emerging clinical success and are 
advancing towards the potential to treat some of the most highly prevalent 
conditions such as neurodegenerative and cardiovascular disorders with limited 
drawbacks. Viral genes are commonly absent in AAV vectors, and they are 
unable to integrate into host-genomes, having been engineered as such 
(Zacchigna, Zentilin, & Giacca, 2014). Patients with a range of diseases from 
congenital blindness (Bennett, et al., 2012), to hemophilia (Nathwani, et al., 
2011), to lipoprotein lipase deficiency (Stroes, et al., 2008) have been targeted 
for the treatment of these conditions by AAV vectors with universal success. AAV 
vectors, compared to other viral gene delivery methods, are able to target 
specific cells of interest without the induction of an inflammatory or otherwise 
immunological response, even upon readministration of the virus (Bennett et al., 
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2012). This heightened ability to target specific cells and reduced risk of systemic 
dissemination of the virus upon administration, makes this vector type favorable 
for use in the clinic for the treatment of a myriad of diseases. Though the simple 
genome limits the size capacity of the therapeutic gene, it is an attractive vector 
candidate also because it provides sustained expression in the target cell.  
Thesis Objectives 
The goal of the present study was to describe the tissue-specific 
expression of AAV vectors by demonstrating their cell-targeting ability in a live 
animal model. Moreover, we sought to develop and optimize a protocol for the 
production, propagation, purification, and characterization of various AAV 
serotypes to determine their tropism and to observe their integrative and 
expressive abilities using different reporter genes in vitro and in vivo.  
To accomplish this goal, we cloned reporter genes luciferase and GFP 
into the transgene cassette. Following this, we identified optimal transfection 
methods and culture conditions, followed by a purification protocol to maximize 
purified virus preparation titer. Finally, we tested the integrative and expressive 
abilities of the reporter genes in vitro – in differentiated neurons from induced 
pluripotent stem cells (iPSCs) – and in vivo – targeting cardiovascular and 
neuronal tissue through intravenous delivery.  
The long-term goal of these projects is to replace the reporter genes with 
specific functional proteins for delivery into the organ systems that we tested in 
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the experiments outlined below. Following successful demonstration of the 
integration of our reporter genes into cardiovascular and brain tissues, we hope 
to use AAV vectors for transgene delivery of: fatty acid oxidation rate-limiting 
protein CPT1B into the heart to rescue the effect of otherwise dysfunctional gene 
products, and Ca2+-signaling-defective gene Pla2g6 which is been implicated in 
familial Parkinson’s Disease. Because the impairment of these genes is limited to 
specific tissue in the disease states, it is necessary to develop a gene transfer 
method that will deliver and allow integration of the transgene into specific tissue 
and provide sustained expression of the new DNA.  
 
 
 
 
 
  
 
 
 
  
  
10 
 
 
 
METHODS 
Animal Model 
All experimental procedures involving animal use were compliant with 
ethical regulations and acquired approval from the Institutional Animal Care and 
Use Committee of Boston University. Animals were maintained in an advanced 
pathogen-free facility with veterinary service and unlimited access to food and 
water. Adult male mice were used for in vivo studies and females were used for 
the derivation of mouse embryonic fibroblasts (MEFs) for GFP experiments. Wild 
type male and female mice both were used for experiments testing for luciferase 
expression.  
Cell Culture 
 Human embryonic kidney-H cells, cloned from the original 293 cell line, 
were acquired from Thermo Fisher (Thermo Fisher 11631017) and cultured in 
serum-free CD 293 suspension medium (Thermo Fisher 11913019) 
supplemented with GlutaMAX (Thermo Fisher 35050061) and Penicillin-
Streptomycin antibiotic (Thermo Fisher 15070063). Cells were first plated as 
adherent cells in Falcon T25 tissue culture flasks (Thermo Fisher 08772) until 
recovered from cryostorage; they were passaged and re-plated in T75 tissue 
culture flasks and were allowed to continue to grow until reaching log phase. 
Cells were transferred to 250 ml polycarbonate Erlenmeyer flasks (Thermo 
Fisher 08772257) to be grown in suspension at 30 ml volume at a rotation speed 
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of 125 rpm at 37 °C and 8% CO2. Cells were passaged upon reaching 2 million 
cells/1 ml volume of medium at ratio of 1:2 every third day.  
 MEFs were isolated from 14.5 day old embryos, and procedure was 
established and carried out by our collaborators in the laboratory of Dr. Victoria 
Bolotina at Boston University. Embryos were genotyped. Head, vertebral column, 
dorsal root ganglia, and internal organs were removed and discarded. Remaining 
embryonic tissue was mechanically dissociated and incubated in 0.25% trypsin 
(Gibco) for 15-30 minutes. Cells from each embryo were plated onto a 10-
centimeter tissue culture dish in Dulbecco’s modified Eagle medium (DMEM; 
Mediatech Inc.) supplemented with 10% fetal bovine serum (FBS), non-essential 
amino acids, sodium pyruvate, and Penicillin-Streptomycin (Invitrogen). Upon 
reaching confluence, primary MEFs from WT embryos were tested and 
confirmed to be free of mycoplasma contamination, and MEFs from passage 2-3 
were studied after 24-48 hr in culture and used for experiments.  
iPSC derived DA neurons from MEFs protocol was performed according 
to procedure previously described by Sommer et. al (2010) by the Bolotina lab at 
Boston University. Approximately 100,000 MEFs were plated in MEF media and 
transduced with constitutive STEMCCA vector at an MOI of 2.5 for a 24 hr 
period. Media was then changed to ESC medium (DMEM with added 15% FBS, 
GlutaMAX, 350K units of ESGRO leukemia inhibitory factor, and 0.1 mM 2-
mercaptoethanol). Medium was changed every second day until appearance of 
  
12 
 
 
 
colonies which were then picked and expanded for STEMCCA excision and 
characterization. Colonies positive for alkaline phosphosphatase, OCT3/4, 
ZFP96, Nanog, and ERas were further expanded and selected for neural 
differentiation. iPSCs were differentiated into DA neurons first by inducing 
formation of embryoid bodies in non-adherent conditions for 4 days in knockout 
serum replacement medium. Cells were then transferred and cultures in ITS 
medium (DMEM/F12 (Gibco), ITS Supplement (Sigma 113146), and 1 µg/ml 
Bovine fibronectin (Sigma F1141)) for 6-10 days to induce ectoderm formation. 
Cells were further expanded and neural identity confirmed by staining against 
beta-III tubulin and nestin. Differentiation into dopaminergic neurons was 
performed by incubating cells for 10 days in minimal medium (DMEM/F12 
(Gibco), N2 Max + Ascorbic Acid (Sigma, A4403)). DA neuron identity was 
confirmed by staining cells for TH (Abcam ab 76442), Dopamine transporter 
(DAT, Abcam ab5990), and vesicular monoamine transporter 2 (VMAT2, Abcam 
70808).  
Restriction Digests and Gel Electrophoresis 
 Plasmids were digested with restriction enzymes to confirm DNA identity. 
Restriction enzymes were acquired from New England Biolabs. 1 µl of enzyme 
was introduced to reaction tube with 1 µl corresponding salt buffer, up to 10 µg 
DNA, and PCR-grade H2O to 50 µl total volume. Sample was incubated in 37 °C 
water bath for 1-1.5 hr.   
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One percent agarose gels were prepared by measuring 3.5 g powdered 
agarose and adding to 1X TAE (Tris, Acetic Acid, and EDTA) with 3.5 µl GelRed 
– a nucleic acid stain to intercalate with DNA as an alternative to conventional 
ethidium bromide. Gel was poured into mold with an 8-lane comb while still in 
liquid phase. After cooling, 10 µl of digested DNA product was added to each 
lane and electric current was applied. Gel was run at 90 V for 30 min to separate 
DNA bands according to size. Bands were visualized under ultraviolet light and 
analyzed using Molecular Analyst DNA software.  
Terrific Broth Preparation 
 Added the following to 900 ml deionized H2O: 12 g bacto-tryptone, 24 g 
bacto-yeast extract, and 4 ml glycerol with 0.17 M KH2PO4 and 0.72 M K2HPO4. 
Added 50 µg/ml Ampicillin or Neomycin based on specific plasmid resistance 
gene. 
Plasmid Preparation 
 Plasmid expressing GFP under synuclein promoter control was a kind gift 
from Dr. Tsuneya Ikezu at Boston University. Plasmid expressing the firefly 
luciferase gene under the ubiquitous CMV promoter was purchased from 
Addgene (plasmid #41045). Plasmid DNA for serotype and packaging viral gene 
expression was acquired from the University of Pennsylvania Vector Core 
(pAAV2/5, pAAV2/1, pAAV2/8, pAAV2/9, and 
pAAVH1.shRLuc.CMV.ZsGreen.SV40). Firefly luciferase was cloned into the 
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AAV expression vector from the donor plasmid PGL3 using restriction digests 
and blunt-ending technique followed by ligation. Plasmid was sequenced using 
the primer 5’ CTAGCAAAATAGGCTGTCCC 3’.  
Plasmids arrived in stab cultures that were used to inoculate overnight 
bacterial cultures in 8 ml terrific broth. Cultures were harvested and spun at 
5,000 rpm for 10 minutes for Miniprep plasmid purification using Qiagen protocol 
(27104). Bacterial cells were pelleted and suspended in 250 µl resuspension 
buffer with RNase A. Following this, 250 µl of alkaline lysis buffer was added for 
5 min. Lysis reaction was neutralized with acidic neutralization buffer, followed by 
centrifugation in 1.5 ml Eppendorf tubes in tabletop centrifuge for 10 min at 
17,900 x g. Supernatant was transferred to spin column for DNA capture which 
was spun at maximum speed for 1 min. Flow-through was discarded. Binding 
buffer was added and the column spun again with flow-through discarded. 
Column was washed with 750 µl ethanol, spun twice, and flow-through 
discarded. Column was transferred to 1.5 ml Eppendorf collection tube. Ten µl 
elution buffer was added, column was incubated for 5 min, and then was spun at 
maximum speed for 1 min. Final DNA concentration was measured using 
NanoDrop spectrophotometer.   
Maxiprep plasmid purifications were carried out according to Qiagen 
protocol (12162). Overnight 50 ml cultures were prepared from glycerol stocks of 
original overnight bacterial culture with addition of 50 µg/ml Ampicillin. Prior 
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protocol described for harvest of overnight culture, resuspension, and lysis was 
followed but with volume of 6 ml for buffers. During first tabletop centrifugation, 
Maxiprep column was equilibrated with addition of 10 ml Buffer QBT followed by 
wash with Buffer QC. DNA was eluted and then precipitated with isopropyl 
alcohol, followed by wash with 70% ethanol. DNA was centrifuged at maximum 
speed in tabletop centrifuge for 10 minutes and supernatant was decanted. Final 
DNA pellet was resuspended in Buffer TE and yield measured using NanoDrop 
spectrophotometer.  
Brain Slices: Preparation, Immunostaining 
 Brains were acquired for analysis by the laboratory of Dr. V. Bolotina at 
Boston University. Under anesthesia, Paav2/5-SYN-GFP was stereotaxically 
injected (1 µl at 0.2 µl/min) in the left hindbrain (bregma AP -2.8 mm; LM -1.3 
mm, DV -4.2 mm). Four weeks following injection, whole brains were sampled for 
immunohistochemistry and Western blot analyses.  
Brains were extracted from WT male mice following 4% paraformaldehyde 
perfusion and cryopreservation in 30% (w/v) sucrose solution at 4 °C. Brain 
sections were acquired by following procedure established by Jackson-Lewis and 
Przedborski (2007). Brains were sectioned in 30-40 µm sections using a cryostat 
microtome, collected as free-floating sections in 24-well plate, and frozen at 4 
°Celsius. Immunostaining was performed using chicken polyclonal antibody 
(Abcam ab76642). Goat anti-chicken Alexa594 secondary antibody was applied 
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at 1:1000. DAPI stain was also used to label nuclei and identify all cells present 
in the section.  
Sections were imaged using the Nikon Ti inverted fluorescence 
microscope equipped with a Perfect Focus system and environmental chamber 
(InVivo Scientific). Images were acquired using a X60/1.4 Plan-Apochromat oil 
immersion Nikon objective lens and filter set for GFP (excitation 465-496, 
emission 515-555). 
Acidified PEI  
 Acidified polyethylenimine (PEI) was prepared for 293-H transfection 
experiments as a cost-effective alternative to other commercially-available 
reagents according to the established protocol by Fukumoto (2010). Linear PEI 
with (molecular weight 25,000; Polysciences Inc. 23966-2) was dissolved in 0.2 
N HCl at 5 mg/ml. Resulting solution had pH 1.0. Aliquot were prepared and 
frozen at -80 °C; avoid freeze-thaws. 
Cell Transfection and Viral Transduction  
 293-H suspension cells were transfected with plasmid using acidified PEI 
in an optimized protocol. Cells were grown to ~3-4 million cells/ml prior to 
transfection. Before transfecting, CD 293 medium was replaced with 25 ml fresh 
DMEM containing 10% FBS. 30 µg of each plasmid DNA was added to 1.5 ml of 
serum-free medium. 75 µg (15 µl stock PEI) was diluted in separate tube in 1.5 
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ml of serum-free medium. The two solutions were combined and gently vortexed 
to mix. Combined solution was incubated at room temperature for 20-60 min. The 
solution was then combined with 2 ml fresh DMEM and added drop-wise to flask. 
Flask was returned to incubator and rotated at 125 rpm at 37 °C and 8% CO2. 
DMEM was replaced with CD 293 medium after 3-4 hr. Cells were collected and 
harvested after 3-4 days, spun at 500 x g for 5 min, and pellets frozen after 
discarding the supernatant (left ~5 ml of medium in tube, however).  
To test for successful AAV transduction in MEFs, 1 ul of purified AAV was 
introduced into media and cells were incubated for 24-48 hr prior to imaging. 
Iodixanol/Optiprep Preparation 
 The following solutions were prepared to be used in virus purification: 10X 
PBS with 10 mM MgCl2 and 20 mM KCl (solution B), PBS with 10 mM MgCl2 and 
20  mM KCl (solution C), 2 M NaCl in solution C (solution D), 54% iodixanol in 
solution B (solution E). From these, the following solutions were prepared to be 
layered for the gradient: 15% iodixanol containing 1.5 volumes of solution E with 
2.7 volumes of solution D and 1.2 volumes of solution C; 25% iodixanol 
containing 2.5 volume of solution E and 2.9 volumes of solution C; 40% iodixanol 
containing 4.0 volumes of solution E and 1.4 volumes of solution C; 54% 
iodixanol containing 9 volumes of iodixanol/Optiprep and 1 volume of solution B. 
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AAV Purification 
 Retrieved frozen pellet of transfected and harvested 293-H cells and 
subjected to 3-4 freeze-thaw cycles by alternating between -80 °C and room 
temperature and 37 °C water bath to lyse cells. For the last thaw cycle, prior to 
the isolation procedure, 1 ul benzonase (E1014 Sigma) per 1 ml medium was 
added to disrupt cell particles. Pellet was incubated with the nuclease in 37 °C 
water bath, shaking every 15 min. 
 Following incubation, resuspended pellet was centrifuged at 1800 rpm for 
5 min. The supernatant was transferred to 1.5 ml Eppendorf tube and centrifuged 
in a tabletop centrifuge and spun at maximum speed for 5 min, ensuring that it 
was as clarified as possible. Gradient in polypropylene ultracentrifuge tubes was 
layered as follows: 1 ml of 54% iodixanol, 3 ml of 40% iodixanol, 3 ml of 25% 
iodixanol, and 1 ml 15% iodixanol. Solutions were introduced into centrifuge tube 
using sterilized needle, syringe, and pipette in order of decreasing density using 
gentle overlayer technique. Tubes were sealed atop with heated metal surface. 
Tubes were balanced, and then were loaded in ultracentrifuge rotor. Tubes were 
spun 6-16 hours at 100,000 x g. Following spin, tubes were suspended, sterilized 
with alcohol wipes, and prepared for virus band extraction. Complete AAV 
particle band was observed between 25%-40% layer, with less distinct, empty 
AAV-particle band observed higher up. Using sterile technique, one 18-gauge 
needle was used to pierce top of plastic tube to allow smooth extraction of the 
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viral band below. A syringe with 18-gauge needle was used to pierce below the 
viral band and extract it by facing the bevel up. Following extraction and removal, 
the virus was added to a dialysis cassette (Thermo Fisher 66205) for overnight 
dialysis in HNE Buffer (50 mM HEPES, 0.15 M NaCl, 25 mM EDTA); buffer was 
replaced periodically to ensure tonicity required was reached. Final purified AAV 
product was quantified, aliquoted, and frozen at -80 °C.  
AAV Titer Quantitation 
 Bovine serum albumin (BSA) standards were prepared of the following 
amounts: 1333 ng BSA, 667 ng BSA, 333 ng BSA, 167 ng BSA, 83 ng BSA, and 
42 ng BSA. 12 µl of purified virus were aliquoted in 1.5 ml Eppendorf tube. 2 ul of 
6X Sodium dodecyl sulfate Laemmli buffer were added to each tube of 12 µl 
standard and virus. All samples and standards were boiled at 95 °Celsius for 3 
min. Following denaturation, standards and virus were loaded on 12% 
polyacrylamide gel and run at 200 volts for 30 min. Gel was removed from 
apparatus and rinsed with deionized H2O three times for 5 min each. Coomassie 
G250 stain was added to gel overnight on rotator at 4 °C. The gel was rinsed the 
following day in deionized H2O until it was clear with distinct blue bands. The gel 
was imaged using the Odyssey Infrared Quantitative Imaging System (LI-COR 
Biosciences) on the 700 channel. Bands were identified and boxed, information 
was exported in Excel report, and protein quantity per AAV particle determined 
with linear regression analysis.  
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Luciferase Detection  
 Mice were prepared for tail vein injections with purified AAV by anesthesia 
with isoflurane. Once unconsciousness, up to 250 µl of purified virus for total of 
approximately 1x10^11 AAV particles was injected into tail veins using 27-guage 
needles, beveled up. Mice were imaged after a minimum of two weeks using the 
IVIS bioluminescent imaging system; D-luciferin was first prepared at 15 mg/ml in 
PBS. This solution was injected into the test and control mice intraperitoneally at 
10 µl per gram of body weight 10-15 min prior to imaging. Mice were then 
anesthetized and placed in IVIS imager to detect bioluminescent signal. 
 Following IVIS imaging for the in vivo study, mice were anesthetized and 
sacrificed using cervical dislocation. Mouse organs were extracted including 
tissue from the heart, skeletal (quadricep) muscle, spleen, lung, and liver. The 
tissues were homogenized, and 50 µl of sample were loaded onto a black-bottom 
96-well plate. Twenty µl of luminol substrate was added immediately prior to 
loading plate into a TECAN bioluminescent plate reader. Samples were loaded 
and luminescence measure in arbitrary light units to determine relative intensity 
of signal.   
qRT-PCR 
 A quantitative assessment of firefly luciferase gene expression was 
performed at the transcript level of tissues extracted from the mice that 
underwent AAV vector treatment and IVIS imaging. Mice were euthanized and 
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their heart, lung, liver, quadricep muscle, kidney, and adipose tissues were 
removed. The tissues were homogenized and RNA was extracted using sterile 
technique. The mRNA was reverse transcribed to cDNA which was then 
analyzed by qRT-PCR. Taqman primers for luciferase gene detection were 
added, and Rsp18 was used as a control (Luciferase TaqMan AF093683_Luc.0 
FAM-MGB kit, Catalog #4448892).  
   
 
 
 
  
  
22 
 
 
 
RESULTS AND DISCUSSION 
Optimization of Virus Purification Protocol 
 Various transfection reagents and protocols were tested against acidified 
polyethyleneimine (PEI) to determine greatest transfection efficiency including 
greatest rate of integration of DNA material into 293-H cells while avoiding using 
excessive quantities of transfection reagent so as to limit potential cytotoxic 
response. Transfection efficiency of PEI is dependent on the ratio of PEI to DNA. 
We tested differing ratios of PEI to DNA, and found greatest virus assembly and 
production to occur at 75 µg PEI combined with 30 µg per each of three AAV 
DNA plasmids. The original Fukumoto protocol detailed culture conditions of 
adherent cells different from the conditions in which we maintained our 293-H cell 
cultures. Furthermore, they described replacing PEI-containing medium with 
fresh medium 8-12 hours following transfection. We shortened the incubation 
time with the PEI-DNA polyplex to limit potential cytotoxic effects of the PEI. 
Following transfection, we varied days-to-harvest periods to maximize virus 
particle output; we found we acquired the greatest yield after 4 days, and thus 
determined to collect cells 4 days post-transfection. A representation of the 
optimized AAV generation protocol is presented in Figure 1.  
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Determination of Virus Particle Titer 
 Following optimization of the virus purification process, we then tested 
various methods for the determination of our purified preparation yield. Figure 2 
depicts the result of an analysis using SDS-PAGE followed by treatment with 
Coomassie Brilliant Blue G250 stain and infrared scanning with the Licor Odyssey 
scanner. A dilution of a series of bovine serum albumin (BSA) standard was 
detected along with a single quantity of the AAV2/5-SYN1-eGFP virus. Following 
the scan, the quantity of BSA nanograms loaded were plotted against the 
background-corrected fluorescence intensity of the bands. Linear regression 
analysis was performed and yielded an equation for the calculation of the 
nanograms of VP3 in the virus sample loaded. The protocol by Kohlbrenner et al. 
(2012) described the determination of the peptide sequence of VP3 and general 
acceptance of 50 VP3 molecules per viral capsid to calculate that each AAV 
particle contains 4.97x10-9 ng of VP3. Using this, we divided the nanograms of 
VP3 determined by the gel method by the nanograms of VP3 per virus particle to 
determine the viral titer.  
 The final titers for the virus purifications we completed thus far are listed in 
Table 1. Corresponding target tissues based on the virus serotype are also listed, 
and were derived from the catalog information made available by the Penn Vector 
Core. The average AAV titer was 3.82 x 1011PFU/µl. Following successful 
generation and purification of the vectors described in the table, our next step is 
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the production of AAV vectors with therapeutic genes for transgene delivery to the 
brain and cardiac tissue specifically.  
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Tissue-Specific Expression of eGFP in Neuronal Cells In vitro and In vivo 
 Cell-specific targeting ability of AAV2/5-SYN1-eGFP was demonstrated 
through treatment of mouse embryonic fibroblast (MEF) cells with purified virus. 
MEFs were used a negative control to show the reliance of transgene expression 
on serotype of the AAV vector (Figure 3).  
 Dopaminergic (DA) neurons derived from human induced pluripotent stem 
cells (iPSCs) were maintained in the laboratory and transduced with the reporter 
gene-containing vector as a positive control. DA cells positively stained for 
neuronal markers Tuj1 and tyrosine hydroxylase, had apparent expression of the 
reporter eGFP. This suggests that expression of the gene carried by the AAV 
vector is specifically driven by serotype and promoter (Figure 4). The same 
phenomenon was positively observed in iPSCs of mouse origin as well (Figure 5).  
 Following this, the activity of the virus was then tested in vivo. Mice were 
injected with AAV2/5-SYN1-eGFP using stereotaxic surgery technique to deliver 
the virus directly into the substantia nigra segment of the brain. Mice were 
sacrificed four weeks following the virus delivery, and their brains were sectioned 
and mounted for immunohistochemistry. Here we demonstrated the activity and 
specificity of the vector through detection of co-localized mouse tyrosine 
hydroxylase (neuronal marker) and GFP immunofluorescence in vivo (Figure 6).  
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Tissue-Specific Expression of Firefly Luciferase Gene 
 Wild type mice were injected with 250 µl of purified AAV2/1-firefly 
luciferase, AAV2/9 firefly luciferase, or saline control to determine whether the 
vector can specifically target and induce reported gene expression in specific 
tissues according the virus serotype. No firefly luciferase gene expression was 
observed, suggesting unsuccessful integration of the gene of interest into the 
transgene cassette (Figure 7). Virus particle assembly was not affected since a 
sizeable band was observed and extracted at the final stage of the differential 
centrifugation step of the virus purification process.  
 Luminescence is given in arbitrary values (right) and corresponds to 
relative intensity of the signal. The control in this experiment exhibited greatest 
signal, though it still falls below the recommended 600-count for the lower limit of 
detection for IVIS. Mice injected with test vector gave an artifactual signal around 
the abdominal area; this was likely as a result of the substrate D-luciferin injected 
intraperitoneally into the cavity prior to imaging and is not likely to be a true 
signal. 
 Following this experiment, we measured luciferase activity in tissues 
harvested from the AAV-treated mice. We extracted heart, liver, lung, quadricep 
muscle, and spleen tissue from AAV2/1 and AAV2/9 mice and performed a plate 
assay to look for bioluminescent signal against tissues from control mice. Results 
demonstrate no discernible pattern of expression in tissues harvested from 
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vector-treated tissues versus control. The absence of a consistent pattern of 
luciferase activity suggests there was no expression of the reporter gene (Figure 
8). 
To better determine whether there was expression of the firefly luciferase 
gene in the AAV preparations used to inject the mice, we extracted additional 
tissues from mice injected with AAV2/9 and performed qRT-PCR analysis. 
Similar to what was demonstrated in the plate assay, there was no corresponding 
expression in the tissues that were to be targeted by the specific serotype; that 
is, there was greater intensity of signal in adipose tissue, quadricep muscle, and 
kidney tissue than in the heart, lung, and liver; likely this is background signal 
that was detected. Additionally, there was no significant difference between the 
level of expression across control and AAV-injected samples. This further 
compounded the finding of the luciferase plate assay, which suggested 
insufficient introduction of the reporter gene into the donor AAV vector (Figure 8).   
Upon examination of the sequencing results of the firefly luciferase gene 
into the donor AAV plasmid, we found there was not complete integration of the 
reporter, thus leading to the unsuccessful detection of the Luciferase gene 
product in the mice. 
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Conclusion and Future Directions 
 In the present study, we were successful in establishing a protocol for the 
generation of functional AAV vectors. We tested the production of the virus 
particles in adherent versus suspension cells and found the latter to produce 
greater quantities of mature particles at a faster rate. Cells in suspension were 
extremely well-suited for bulk virus production as there was less use of materials 
involved in the maintenance of those cells in culture. Suspension cell growth was 
only limited by concentration of cells in the medium; this could be controlled by 
passaging the cells daily or by diluting with addition of extra medium to maintain 
the cells in log phase. The suspension cells required no enzymatic or mechanical 
dissociation, and we found them to be robust in the production of AAVs once 
transfected. We also successfully utilized ultracentrifugation as a purification 
method for complete virus particles. This was used as an alternative to another 
common purification technique which involves the use of ion exchange 
chromatography. We preferred the iodixanol method because the size of AAVs 
limits the use of chromatographic resins in protein purification (Oksanen et al, 
2012), and each serotype would require a different chromatographic method 
based on their surface properties. In addition, the chromatographic method would 
not allow distinction between empty and intact virus particles – a difference that 
is easily discernible when using the iodixanol method.  Ultimately, we found 
ultracentrifugation to be efficient and easily scalable for the potential future 
production of large quantities of virus particles.  
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In testing the function of our viral vectors, we were able to successfully  
demonstrate the ability of neurons and neuronal promoters to drive expression of 
the reporter eGFP gene delivered via the AAV2/5 serotype. In future, we would 
seek to incorporate a therapeutic gene, PLA2 – a protein that has been 
implicated in the pathophysiology of Alzheimer’s Disease – to be cloned into the 
original AAV transgene cassette for delivery into the substantia nigra of the brain 
where it can potentially rescue the function of the mutated protein.   
We were unable to successfully demonstrate integration and expression of 
the reporter firefly luciferase gene into target tissue with serotypes AAV2/1 and 
AAV2/9. This is likely due to the inaccuracy in our cloning technique since we 
were unable to successfully show complete insertion of our transgene into the 
AAV expression vector through sequencing. It is not likely that transfection or 
virus assembly was compromised; this is evidenced by the presence of 
prominent viral bands in the iodixanol centrifugation step of the experiment. In 
future, we would seek to confirm the appropriate gene sequence cloned into the 
expression plasmid, and then follow with demonstration of accurate integration 
and expression of the viral genes.  
Upon repeated demonstration of the successful integration of reporter 
gene-containing AAV vectors into target cells, our next step would be to 
determine levels and durations of expression of the transgenes. We sought to 
characterize the functions and capabilities of the AAV vector and to use it as a 
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gene delivery tool for conditions that cannot tolerate the toxicity or non-specificity 
of alternative methods. While the present study focused primarily on the 
characterization of the AAV vector based on its tropism, there is vast potential if 
we continue to explore its capabilities in a multitude of disease types. Our aim is 
to continue to hone the AAV generation process and to ultimately use this viral 
vector as a therapeutic tool.  
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